Become A Featured Company

cbdMD Sales Growing, Key Influencers Continue to Bring the Product Mainstream

Ryan Allway

September 17th, 2019

App, Exclusive, Top News

 

CBD, or cannabidiol, has moved into the mainstream, a normalization process that has been supported by several regulatory and legislative events. The framework may be on the government side, but consumer uptake is being accelerated by key influencers promoting brands while educating the public on these events, as well as the potential benefits of CBD.

The market adoption has been wide and sweeping, fueled by endorsements from celebrities and superstars covering all generations. For example, the likes of Martha Stewart, Snoop Dogg, Wiz Khalifa, Kim Kardashian, Emma Roberts, and many more have jumped in to support the wellness attributes of CBD, creating exposure to demographics from Baby Boomers to older Gen Z-ers.

Click here to receive an investor deck and corporate updates

Athletes Cheer for CBD

Athletes, in particular, are standing up and cheering the effects of CBD for a wide range of uses. Three-time Super Bowl Champion Rob Gronkowski, who surprised many by announcing his retirement from the NFL in March, is the latest high-profile athlete to bemoan today’s addictive drugs and advocate for CBD application.

There probably isn’t a more distinguished group of athletes endorsing one particular brand than cbdMD, Inc. (NYSE American: YCBD), a nationally recognized consumer cannabidiol brand and the first NYSE-listed pure CBD play. The company offers a full line of award-winning premium CBD products, including oil tinctures, topicals, capsules, gummies, pet products, bath bombs and more.

The star-studded Team cbdMD lineup includes former NFL stars Steve Smith, Sr. and Jonathan Stewart, pro beach volleyball legend Kerri Walsh Jennings, pro golfers Bubba Watson and Mark Anderson, All-American and Olympic star Lolo Jones, MMA stars like recent UFC heavyweight champion Daniel Cormier and Quinton “Rampage” Jackson, and a bevy of extreme sports heroes.

Click here to receive an investor deck and corporate updates

It takes an elite athlete to make it to the professional level, combined with the constant pushing and abuse of the body to remain competitive at the highest level. Sadly, the story has been the same from most professional athletes with complaints of more traditional prescriptions being the norm. For Steve Smith, Sr., working with cbdMD has become a family affair underscored by what CBD has done for him personally after 16 years in the NFL – during which he racked up the seventh most all-purpose yards in NFL history.

“I’m proud to step forward and say that this partnership can be the platform the public needs to educate themselves on the power of CBD,” Smith said about his relationship with cbdMD.

Golf icon Bubba Watson, who needed to have cbdMD fully vetted before being allowed to endorse or use its products to ensure it was safe and in compliance with all PGA rules, has been quoted as saying, “I’ve personally felt the benefits of cbdMD’s products. cbdMD is the safest on the market and I am proud to partner with them to help millions feel better.” Watson says he takes cbdMD products to help with recovery and better sleep functions.

Bubba Watson, Pro Golfer

There are some common threads that run through athletes promulgating the benefits of CBD: safety and education.

Like no other marketing or education could do, these influencers are removing the stigma attached to cannabis. Amongst other things, they are informing people that there is a night-and-day difference between CBD and THC (tetrahydrocannabinol), the two most well-known active components of cannabis, called cannabinoids. CBD is non-intoxicating, whereas THC is the cannabinoid responsible for the psychoactive high commonly linked to marijuana.

All cbdMD products are tested by an independent third-party lab and are guaranteed THC-free.

The Regulatory Catalysts

Athletes wouldn’t be in a position to put their stamps of approval on products in the way that they are if it weren’t for specific developments recently. Namely, these are the 2018 Farm Bill, Canada’s legalization of cannabis in October 2018, and the U.S. Food and Drug Administration approving GW Pharma’s (NASDAQ: GWPH) Epidiolex.

President Donald Trump’s signing of the Agriculture Improvement Act of 2018, better known as the Farm Bill, had a profound impact on the CBD market by federally legalizing hemp. Hemp is defined as any part of the plant Cannabis sativa that contains less than 0.3% THC.

What hemp does have is CBD. Effectively, the passage of the Farm Bill opened a national discussion for interstate commerce of hemp-derived CBD products without fear of federal backlash.

Click here to receive an investor deck and corporate updates

Canada made history when it became the first industrialized country (and second only to Uruguay) to legalize recreational marijuana. Lawmakers didn’t rush into legalizing cannabis with broad strokes. Only certain forms of cannabis became legal last October, with a pin put in other types (such as edibles, concentrates, and creams) until laws could be hammered out.

Expectations are for new laws to be enacted by the end of the year, which will open up a whole new market for CBD in Canada.

Talk of “descheduling” or “rescheduling” cannabis is increasing in volume. As it stands, cannabis is a Schedule I drug at the federal level alongside heroin and LSD. By definition, these drugs have no currently accepted medical use and have a high potential for addiction. However, in June 2018, the FDA approved Epidiolex (which has CBD as its active pharmaceutical ingredient) for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

The full acceptance into the world of pharmaceuticals shoots down the idea that CBD has no medical benefit. It also gives CBD advocates additional evidence to argue that cannabis needs to be rescheduled, which will pave the way for additional clinical work studying its efficacy for hard-to-treat diseases and conditions.

Awakened Market, Increasing Sales

Against this backdrop, key influencers are making a meaningful impact on the young CBD market. Many consumers – if not most – didn’t realize that CBD was a bigger part of the national discussion in terms of the legal medical marijuana movement; not to mention the worldwide consideration as more people are opening up to the possibilities of CBD and cannabis. The aforementioned developments, though, created greater awareness. The Farm Bill was particularly important for companies focused exclusively on hemp-based CBD, like cbdMD, because constraints on commerce and logistics were ultimately removed.

Click here to receive an investor deck and corporate updates

Still, a groundswell is underway and Americans are now becoming increasingly educated on the qualities and characteristics of CBD, a process that continues to widen sales channels to feed consumer demand as CBD is normalized in the marketplace.

With a growing choir of voices singing the praises of CBD, demand isn’t expected to wane any time in the foreseeable future. That is good news for cbdMD, which saw net sales rise 42% from Q1 2019 to $8.04 million in the second quarter, ended June 30, 2019.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading